“As was requested by the Committee when we appeared before you on February 26, 2004, we have provided the Committee with our supplementary submissions regarding the alternatives to the ‘right of refusal’ that had been proposed to the Committee…
“However, discussions at subsequent Committee meetings have indicated that Committee members are under a fundamental misapprehension with regard to another key aspect of our submission — namely, the concern that Bill C-9 excludes the possibility of NGOs procuring lower-cost pharmaceutical products from Canadian generic producers.
“We are concerned that Committee members have an incorrect impression of the concern that NGOs have raised. . . .”